Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
NEKTAR THERAPEUTICS
| Metric | NEKTAR THERAPEUTICS NKTROther |
|---|---|
| Quality Score | 17 / 100 |
| Revenue (latest) | $55M |
| Net income (latest) | −$164M |
| Operating margin | −253.7% |
| Net margin | −297.1% |
| Return on equity | −182.6% |
| Return on assets | −58.5% |
| Return on capital (ROCE) | −61.8% |
| Debt / equity | 2.12× |
| Revenue growth (YoY) | −43.9% |
| Altman Z″ (distress) | -41.60 |
| Accruals / assets | 15.8% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.